1. Executive Summary
2. United States Pneumococcal & Meningococcal Vaccines Market Size & Analysis (2015 - 2025)
3. United States Pneumococcal Vaccines Market Size & Analysis (2015 - 2025)
4. United States Meningococcal Vaccines Market Size & Analysis (2015 - 2025)
5. United States Pneumococcal & Meningococcal Vaccines Market Share & Y-o-Y Growth (%), 2017 - 2025
5.1 United States Pneumococcal Vaccines Market Share & Y-o-Y Growth (%), 2015 - 2025
5.2 United States Meningococcal Vaccines Market Share & Y-o-Y Growth (%), 2017 - 2025
6. Key Drivers and Inhibitors of the United States Pneumococcal & Meningococcal Vaccines Market
6.1 Market Drivers
6.2 Market Inhibitors
7. United States Pneumococcal & Meningococcal Vaccines Market Assessment & Opportunity (Value),2015 - 2025
7.1 Prevnar / Prevnar 13
7.2 Pneumovax 23
7.3 Menactra
7.4 Bexsero
7.5 Menveo
7.6 Trumenba
8. United States Pneumococcal & Meningococcal Vaccines Pricing Trends & Analysis
9. United States Pneumococcal & Meningococcal Vaccines Reimbursement Policies & Regulatory System
9.1 Reimbursement Policies
9.2 Regulation System
10. Promising Pneumococcal & Meningococcal Vaccines in Clinical Development
11. Major Deals in the Vaccines Market
11.1 Merger & Acquisitions
11.2 Collaboration Deals
11.3 Licensing Agreement
11.4 Exclusive Agreement
11.5 Distribution Agreement
11.6 Partnerships
12. Key Companies Analysis
12.1 Sanofi Pasteur
12.1.1 Business Overview
12.1.2 Vaccines Portfolio
12.1.3 Recent Development
12.2 GlaxoSmithKline (GSK)
12.2.1 Business Overview
12.2.2 Vaccines Portfolio
12.2.3 Recent Development
12.3 Merck
12.3.1 Business Overview
12.3.2 Vaccines Portfolio
12.3.3 Recent Development
12.4 Pfizer
12.4.1 Business Overview
12.4.2 Vaccines Portfolio
12.4.3 Recent Development